Argus analyst David Toung upgraded Integra LifeSciences (NASDAQ: IART) from Hold to Buy with a price target of $25.00.

The analyst comments "Upgrading to BUY • A change in the executive suite gives us confidence that an earnings turnaround is at hand at Integra and more consistent growth is in the offing. • The company has resolved production issues and will now be able to meet customer demand for tissue and skin regenerative products. • The company recently topped 1Q EPS expectations, and management raised guidance. • Valuations are still low; our target price is $25."

For an analyst ratings summary and ratings history on Integra LifeSciences click here. For more ratings news on Integra LifeSciences click here.

Shares of Integra LifeSciences closed at $17.20 yesterday.